Pill Identifier App

Generic Ablavar Availability

Ablavar is a brand name of gadofosveset trisodium, approved by the FDA in the following formulation(s):

ABLAVAR (gadofosveset trisodium - solution;intravenous)

  • Manufacturer: LANTHEUS MEDCL
    Approval date: December 22, 2008
    Strength(s): 2440MG/10ML (244MG/ML), 3660MG/15ML (244MG/ML) [RLD]

Has a generic version of Ablavar been approved?

No. There is currently no therapeutically equivalent version of Ablavar available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ablavar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Diagnostic imaging contrast agents with extended blood retention
    Patent 6,676,929
    Issued: January 13, 2004
    Inventor(s): Thomas J.; McMurry & Hironao; Sijiki & Daniel M.; Scott & Randall B.; Lauffer
    Assignee(s): Epix Medical, Inc.
    The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Patent expiration dates:
    • May 4, 2020
      ✓ 
      Drug product
  • Diagnostic imaging contrast agents with extended blood retention
    Patent 7,011,815
    Issued: March 14, 2006
    Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
    Assignee(s): Epix Pharmaceuticals, Inc.
    The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Patent expiration dates:
    • February 1, 2015
      ✓ 
      Patent use: METHOD OF MR IMAGING OF A MAMMAL
  • Diagnostic imaging contrast agents with extended blood retention
    Patent 7,060,250
    Issued: June 13, 2006
    Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
    Assignee(s): Epix Pharmaceuticals, Inc.
    The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Patent expiration dates:
    • May 26, 2015
      ✓ 
      Drug substance
  • Diagnostic imaging contrast agents with extended blood retention
    Patent 7,229,606
    Issued: June 12, 2007
    Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
    Assignee(s): Epix Pharmaceuticals, Inc.
    The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Patent expiration dates:
    • May 26, 2015
      ✓ 
      Patent use: METHOD OF MR IMAGING OF A MAMMAL
  • Diagnostic imaging contrast agents with extended blood retention
    Patent 8,017,105
    Issued: September 13, 2011
    Inventor(s): McMurry; Thomas J. & Sijiki; Hironao & Scott; Daniel M. & Lauffer; Randall B.
    Assignee(s): Lantheus Medical Imaging, Inc.
    The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Patent expiration dates:
    • May 26, 2015
      ✓ 
      Drug substance
  • Diagnostic imaging contrast agents with extended blood retention
    Patent 8,394,356
    Issued: March 12, 2013
    Assignee(s): Lantheus Medical Imaging, Inc.
    The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Patent expiration dates:
    • February 1, 2015
      ✓ 
      Patent use: METHOD OF MR IMAGING OF A MAMMAL

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 22, 2013 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)